Now that multiple prevention clinical trials for rheumatoid arthritis (RA) have been completed, a group of investigators have reviewed the results and published their recommendations for future trial designs and drug development to assess interventions that may alter disease development.
All News
Article
Article
The results of a randomised, open-label, head-to-head trial shows that adalimumab was superior to ciclosporin in preventing uveitis relapses in patients with severe Behçet's disease.
Article
Dr. Jack Cush picks highlight reports from the past week on RheumNow.com, with reports on the challenge of lupus nephritis, perplexing skin issues, you don't know JAK (about Tyk) and the value of a good family history.
Linger on the Fingers (9.6.2024)
Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow. This week with a focus on fingers and better prescriptive follow through.
https://t.co/c9yvRjE9av https://t.co/mdN37AWHjX
CAR-T Like Effects with Bispecific Teclistamab
A new chapter may have begun in the exciting story of "immune reset" therapy for difficult-to-treat autoimmune diseases, with a patient with severe refractory lupus obtaining drug-free remission after treatment with an antibody… https://t.co/uE7QEHc0nx https://t.co/UcenZHv35O
Dactylitis is seen in 50% of PsA patients. Dactylitis is frequently associated with more severe PsA phenotype, often representing the initial feature of the disease. Many agents are effective but no b/tsDMARD is distinguished as being superior in dactylitis.… https://t.co/NKOXReiZYd https://t.co/Ake2fixZ40
Immunomodulatory Prevention of Uveitis Relapse in Behçet's
The results of a randomised, open-label, head-to-head trial shows that adalimumab was superior to ciclosporin in preventing uveitis relapses in patients with severe Behçet's disease.
https://t.co/12fpuIZFmA https://t.co/iDJJq29JMA
Biomarker subanalysis of a phase 3 RCT of SC Abatacept in 219 polyarticular JIA pts. Lower baseline levels of S100A8/9 & S100A12 predicted better response (JIA-ACR90 2.5) at 16 mos. Decr in S100A8/9 & S100A12 @4mos was >50% among responders https://t.co/TWx62EhRBl https://t.co/6uhoRowg3n
Retrospective observational study of 96 stable #SLE pts compared maintenance on HCQ vs belimumab. There were no significant differences in Flare rate (18% HCQ vs 8.3% BLM; p=0.47), damage index increase, SLEDAI, Pred dose or adverse events https://t.co/sVPMugSHn3 https://t.co/6bdel6Kvs9
ACR Backs FDA Rule Change on Interchangeable Biosimilars
The ACR submitted comments to the FDA supporting their proposal to update the approval process for biosimilars’ interchangeability status.
https://t.co/YD11qZJxIr https://t.co/tVij0ebwz4
New $$$ drugs are NOT usually steroid sparing, but a single center 716 RA pt study compared JAKi (n 156) vs bDMARDs (560) starts; JAKi assoc w/ more rapid GC reduction in1st 6 mos & 60% higher odds of GC D/C (adj OR 1.63) (>50% vs 40% @12 mos) https://t.co/shiDytQeBU https://t.co/dCjyw21uLd
Sequential Belimumab and RTX in SLE
Could disease control in active SLE patients be improved by the sequential use of subcutaneous BEL and intravenous RTX? A double blind trial has shown that sequential BEL and RTX was not superior to BEL alone in SLE.
https://t.co/CO0ltRX9Eo https://t.co/zey2UE4BRu
Retrospective study of 919 RTX-treated GPA pts shows TMP-SMX prophylaxis (given to 31%) assoc w/ reduced serious infections (adj HR 0.5) and less outpatient infections (aHR 0.8). All 13 pneumocystis infx (PJP) occured in those not Rx w/ TMP-SMX. https://t.co/bO6oAHv7Lr https://t.co/fPntW75hnY
AR882, a URAT1 inhibitor, was given FDA Fast Track designation for potential treatment of clinically visible tophi in patients with gout. In the US 13 mill have gout & 2 mill have visible tophi. AR882 was presented at EULAR24 https://t.co/StvD3iz9AD https://t.co/G9SzxJysSD https://t.co/KcUSPVb5pn
2024 Update of EULAR recommendations for the Treatment of Systemic Sclerosis
https://t.co/52XEfgVCzZ https://t.co/d1zgTYUeOo
Tyk2 inhibitor/Zasocitinib (TAK-279) effective in Psoriasis. Ph II RDBPCT of 259 pts w/ mod- severe plaque PsO showed 12 week PASI 75 success in 68% & 67% on 15 - 30 mg zasocitinib qd vs Placebo (18%). https://t.co/yyZwBYAP3H https://t.co/TvSSlEAKtR
Biologic Rx may be less effective in psoriasis pts who are older, smokers, w/ Hi BMI & prior biologic use. Metanalysis of 40 studies, 21 438 PSO pts, and PASI90 responses. Decr Response w/ age (OR 0.99), Biologics (0.44), BMI 30+ (0.57), smoking (0.81) https://t.co/uhFFIwNKB7 https://t.co/LaznQ0M9UG
Pulse Steroids with Tocilizumab in Giant Cell Arteritis
A pilot study assessed pulse methoprednisolone with weekly subcutaneous TCZ in patients with large vessel-GCA (LV-GCA) and showed that a sizeable minority will relapse after the TCZ is discontinued.
https://t.co/gGrSY3U1t9 https://t.co/zuspadaY9t
ACR Applauds Lower Negotiated Prices for Common Arthritis Drugs
The ACR praised the recent announcement from the CMS that their initial drug pricing negotiations have reduced costs for select medications, including significantly lower prices for Enbrel and Stelara, which are… https://t.co/GXl6y87ZaF https://t.co/A2N4Ehg8Dk
Severe Alopecia Areata or Universalis - if you stop the JAK inhibitor, Hair loss occurs quickly, but can be recaptured. Severe Alopecia Areata. Substudy of the baricitinib BRAVE-AA1 RCT, 80% of those who D/C vs 8% of those continuing, lost BARI benefits https://t.co/YcfmegdvK6 https://t.co/GIwVy4ac6U
